Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL therapy in advanced breast cancer
NCT05142475Phase 1Recruiting
- Sponsor
- Juncell Therapeutics
- Start
- Nov 2021
- Primary completion
- Dec 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nolgileucel in breast cancer, sponsored by Juncell Therapeutics. Primary endpoints: Adverse Events at 6 months, Objective Response Rate at 36 months and 4 more. Started Nov 2021; status: recruiting.
02
Drugs
nolgileucel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05142475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05142475.